Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Hodgkin Disease 50Lymphoma 45Lymphoma, Large B-Cell, Diffuse 10Lymphoma, Non-Hodgkin 9Lymphoma, Large-Cell, Immunoblastic 6Lymphoma, Follicular 6HIV Infections 5Acquired Immunodeficiency Syndrome 4Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Dendritic Cell Sarcoma, Interdigitating 2Cardiotoxicity 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Nervous System Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Diseases 1Disease 1AIDS-Related Complex 1

Interventions

Brentuximab Vedotin 21Cyclophosphamide 17Rituximab 11fludarabine 9Mycophenolic Acid 9pirtobrutinib 7dacetuzumab 7Busulfan 7fludarabine phosphate 6Tacrolimus 6Melphalan 6Whole-Body Irradiation 5Doxorubicin 5Vincristine 4Prednisone 4Mesna 4Etoposide 4Bone Marrow Transplantation 4Bendamustine Hydrochloride 4ibrutinib 3Thiotepa 3Sirolimus 3Cyclosporine 3Bortezomib 3ponatinib 2Vorinostat 2Stem Cell Transplantation 2Rifampin 2Platelet Transfusion 2Peripheral Blood Stem Cell Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Diseases × Bleomycin × Lymphoid × Clear all
NCT01060904 2014-12-18

A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma

Seagen Inc.

Phase 1 Completed
51 enrolled
Lymphoid

Hematologic Diseases, Hodgkin Disease, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡